vs
Orthofix Medical Inc.（OFIX）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是Rapid7, Inc.的1.0倍（$219.9M vs $217.4M），Rapid7, Inc.净利率更高（1.4% vs -1.0%，领先2.4%），Orthofix Medical Inc.同比增速更快（2.0% vs 0.5%），Rapid7, Inc.自由现金流更多（$36.4M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 3.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
OFIX vs RPD — 直观对比
营收规模更大
OFIX
是对方的1.0倍
$217.4M
营收增速更快
OFIX
高出1.5%
0.5%
净利率更高
RPD
高出2.4%
-1.0%
自由现金流更多
RPD
多$19.6M
$16.8M
两年增速更快
OFIX
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $217.4M |
| 净利润 | $-2.2M | $3.1M |
| 毛利率 | 71.1% | 68.9% |
| 营业利润率 | 0.2% | 1.0% |
| 净利率 | -1.0% | 1.4% |
| 营收同比 | 2.0% | 0.5% |
| 净利润同比 | 92.4% | 44.1% |
| 每股收益（稀释后） | $-0.05 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXRPD
| Q4 25 | $219.9M | $217.4M | ||
| Q3 25 | $205.6M | $218.0M | ||
| Q2 25 | $203.1M | $214.2M | ||
| Q1 25 | $193.6M | $210.3M | ||
| Q4 24 | $215.7M | $216.3M | ||
| Q3 24 | $196.6M | $214.7M | ||
| Q2 24 | $198.6M | $208.0M | ||
| Q1 24 | $188.6M | $205.1M |
净利润OFIXRPD
| Q4 25 | $-2.2M | $3.1M | ||
| Q3 25 | $-22.8M | $9.8M | ||
| Q2 25 | $-14.1M | $8.3M | ||
| Q1 25 | $-53.1M | $2.1M | ||
| Q4 24 | $-29.1M | $2.2M | ||
| Q3 24 | $-27.4M | $15.4M | ||
| Q2 24 | $-33.4M | $6.5M | ||
| Q1 24 | $-36.0M | $1.4M |
毛利率OFIXRPD
| Q4 25 | 71.1% | 68.9% | ||
| Q3 25 | 72.2% | 70.2% | ||
| Q2 25 | 68.7% | 70.6% | ||
| Q1 25 | 62.8% | 71.7% | ||
| Q4 24 | 69.0% | 69.5% | ||
| Q3 24 | 68.7% | 70.6% | ||
| Q2 24 | 67.8% | 70.7% | ||
| Q1 24 | 67.5% | 70.3% |
营业利润率OFIXRPD
| Q4 25 | 0.2% | 1.0% | ||
| Q3 25 | -8.3% | 2.7% | ||
| Q2 25 | -7.9% | 1.6% | ||
| Q1 25 | -25.2% | -0.0% | ||
| Q4 24 | -5.3% | 3.4% | ||
| Q3 24 | -9.6% | 6.0% | ||
| Q2 24 | -12.5% | 2.5% | ||
| Q1 24 | -15.6% | 4.7% |
净利率OFIXRPD
| Q4 25 | -1.0% | 1.4% | ||
| Q3 25 | -11.1% | 4.5% | ||
| Q2 25 | -6.9% | 3.9% | ||
| Q1 25 | -27.4% | 1.0% | ||
| Q4 24 | -13.5% | 1.0% | ||
| Q3 24 | -13.9% | 7.2% | ||
| Q2 24 | -16.8% | 3.1% | ||
| Q1 24 | -19.1% | 0.7% |
每股收益（稀释后）OFIXRPD
| Q4 25 | $-0.05 | $0.05 | ||
| Q3 25 | $-0.57 | $0.15 | ||
| Q2 25 | $-0.36 | $0.13 | ||
| Q1 25 | $-1.35 | $0.03 | ||
| Q4 24 | $-0.76 | $0.08 | ||
| Q3 24 | $-0.71 | $0.21 | ||
| Q2 24 | $-0.88 | $0.09 | ||
| Q1 24 | $-0.95 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $474.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $450.0M | $154.7M |
| 总资产 | $850.6M | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OFIXRPD
| Q4 25 | $82.0M | $474.7M | ||
| Q3 25 | $62.9M | $407.1M | ||
| Q2 25 | $65.6M | $511.7M | ||
| Q1 25 | $58.0M | $493.5M | ||
| Q4 24 | $83.2M | $521.7M | ||
| Q3 24 | $30.1M | $443.7M | ||
| Q2 24 | $26.4M | $442.6M | ||
| Q1 24 | $27.0M | $411.7M |
总债务OFIXRPD
| Q4 25 | — | — | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | — | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXRPD
| Q4 25 | $450.0M | $154.7M | ||
| Q3 25 | $442.5M | $127.2M | ||
| Q2 25 | $458.3M | $90.4M | ||
| Q1 25 | $458.3M | $52.7M | ||
| Q4 24 | $503.1M | $17.7M | ||
| Q3 24 | $525.9M | $-5.1M | ||
| Q2 24 | $546.0M | $-52.6M | ||
| Q1 24 | $570.3M | $-86.4M |
总资产OFIXRPD
| Q4 25 | $850.6M | $1.7B | ||
| Q3 25 | $832.6M | $1.7B | ||
| Q2 25 | $837.2M | $1.6B | ||
| Q1 25 | $823.1M | $1.6B | ||
| Q4 24 | $893.3M | $1.7B | ||
| Q3 24 | $867.9M | $1.6B | ||
| Q2 24 | $882.0M | $1.5B | ||
| Q1 24 | $906.0M | $1.5B |
负债/权益比OFIXRPD
| Q4 25 | — | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | — | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $36.4M |
| 自由现金流率自由现金流/营收 | 7.6% | 16.8% |
| 资本支出强度资本支出/营收 | 4.9% | 0.5% |
| 现金转化率经营现金流/净利润 | — | 12.01× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $146.2M |
8季度趋势，按日历期对齐
经营现金流OFIXRPD
| Q4 25 | $27.7M | $37.6M | ||
| Q3 25 | $12.4M | $39.0M | ||
| Q2 25 | $11.6M | $47.5M | ||
| Q1 25 | $-18.4M | $29.8M | ||
| Q4 24 | $23.7M | $63.8M | ||
| Q3 24 | $11.7M | $44.0M | ||
| Q2 24 | $9.0M | $32.9M | ||
| Q1 24 | $-18.6M | $31.1M |
自由现金流OFIXRPD
| Q4 25 | $16.8M | $36.4M | ||
| Q3 25 | $2.5M | $34.8M | ||
| Q2 25 | $4.5M | $46.6M | ||
| Q1 25 | $-25.1M | $28.4M | ||
| Q4 24 | $15.2M | $62.6M | ||
| Q3 24 | $6.3M | $42.6M | ||
| Q2 24 | $-360.0K | $32.6M | ||
| Q1 24 | $-29.1M | $30.4M |
自由现金流率OFIXRPD
| Q4 25 | 7.6% | 16.8% | ||
| Q3 25 | 1.2% | 16.0% | ||
| Q2 25 | 2.2% | 21.8% | ||
| Q1 25 | -13.0% | 13.5% | ||
| Q4 24 | 7.0% | 28.9% | ||
| Q3 24 | 3.2% | 19.9% | ||
| Q2 24 | -0.2% | 15.7% | ||
| Q1 24 | -15.4% | 14.8% |
资本支出强度OFIXRPD
| Q4 25 | 4.9% | 0.5% | ||
| Q3 25 | 4.8% | 1.9% | ||
| Q2 25 | 3.5% | 0.4% | ||
| Q1 25 | 3.5% | 0.6% | ||
| Q4 24 | 4.0% | 0.5% | ||
| Q3 24 | 2.7% | 0.6% | ||
| Q2 24 | 4.7% | 0.1% | ||
| Q1 24 | 5.6% | 0.3% |
现金转化率OFIXRPD
| Q4 25 | — | 12.01× | ||
| Q3 25 | — | 3.97× | ||
| Q2 25 | — | 5.70× | ||
| Q1 25 | — | 14.14× | ||
| Q4 24 | — | 29.36× | ||
| Q3 24 | — | 2.85× | ||
| Q2 24 | — | 5.03× | ||
| Q1 24 | — | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
